208 related articles for article (PubMed ID: 3871099)
1. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.
Lotze MT; Frana LW; Sharrow SO; Robb RJ; Rosenberg SA
J Immunol; 1985 Jan; 134(1):157-66. PubMed ID: 3871099
[TBL] [Abstract][Full Text] [Related]
2. Systemic administration of interleukin-2 in humans.
Lotze MT; Robb RJ; Sharrow SO; Frana LW; Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):475-82. PubMed ID: 6334135
[TBL] [Abstract][Full Text] [Related]
3. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
Lotze MT; Matory YL; Ettinghausen SE; Rayner AA; Sharrow SO; Seipp CA; Custer MC; Rosenberg SA
J Immunol; 1985 Oct; 135(4):2865-75. PubMed ID: 2993418
[TBL] [Abstract][Full Text] [Related]
4. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.
Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Shuman WP; Levitt D; Fefer A
Cancer Res; 1989 Jan; 49(1):235-40. PubMed ID: 2783243
[TBL] [Abstract][Full Text] [Related]
5. In vivo administration of purified Jurkat-derived interleukin 2 in mice.
Donohue JH; Lotze MT; Robb RJ; Rosenstein M; Braziel RM; Jaffe ES; Rosenberg SA
Cancer Res; 1984 Apr; 44(4):1380-6. PubMed ID: 6608405
[TBL] [Abstract][Full Text] [Related]
6. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
Da Pozzo LF; Hough KL; Holder WD
Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858
[TBL] [Abstract][Full Text] [Related]
7. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
[TBL] [Abstract][Full Text] [Related]
8. In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.
Hank JA; Kohler PC; Weil-Hillman G; Rosenthal N; Moore KH; Storer B; Minkoff D; Bradshaw J; Bechhofer R; Sondel PM
Cancer Res; 1988 Apr; 48(7):1965-71. PubMed ID: 3258180
[TBL] [Abstract][Full Text] [Related]
9. The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.
Rosenthal NS; Hank JA; Kohler PC; Minkoff DZ; Moore KH; Bechhofer R; Hong R; Storer B; Sondel PM
J Biol Response Mod; 1988 Apr; 7(2):123-39. PubMed ID: 3258904
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
11. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
12. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 and lymphokine activated killer cells: promises and cautions.
Glassman AB
Ann Clin Lab Sci; 1989; 19(1):51-5. PubMed ID: 2644890
[TBL] [Abstract][Full Text] [Related]
14. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome.
Siegel JP; Lane HC; Stocks NI; Quinnan GV; Fauci AS
J Biol Response Mod; 1985 Dec; 4(6):596-601. PubMed ID: 3910763
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 clinical evaluation of recombinant interleukin-2.
Kohler PC; Hank JA; Moore KH; Storer B; Bechhofer R; Sondel PM
Prog Clin Biol Res; 1987; 244():161-72. PubMed ID: 3498945
[TBL] [Abstract][Full Text] [Related]
17. High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
Quan W; Ramirez M; Taylor WC; Vinogradov M; Khan N; Jackson S
Cancer Biother Radiopharm; 2004 Dec; 19(6):770-5. PubMed ID: 15665626
[TBL] [Abstract][Full Text] [Related]
18. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
19. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB
Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.
Sondel PM; Kohler PC; Hank JA; Moore KH; Rosenthal NS; Sosman JA; Bechhofer R; Storer B
Cancer Res; 1988 May; 48(9):2561-7. PubMed ID: 3258545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
